Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry. 1994 Sep;55 Suppl A:62-8.
Lecrubier Y, Bourin M, Moon CA et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand. 1997 Jun;95(6):485-93.
Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry. 1997 Sep;58(9):393-8.
Tylee A, Beaumont G, Bowden MW. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry 1997;3:51-58.
Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry. 1997 Sep;9(3):157-64.
Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 1999 Dec;56(2-3):171-81.
Benedictis E. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol. 2000 Mar;14(1):61-6.
Sir A, D'Souza RF, Uguz S et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry. 2005 Oct;66(10):1312-20.
Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry. 2005 Apr-Jun;17(2):65-9.
Smith D, Dempster C, Glanville J et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002 May;180:396-404.
Thase M, Entsuah A, Rudolph R. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241.
Entsuah R, Huang, H, Willard L. Venlafaxine and SSRIs: pooled remission analysis (meta-analysis of 31 studies of >7000 patients). Yokohama, Japan World Congress of Psychiatry (WCP) 2002.
Einarson T. Comparison of extended relase venlafaxine, SSRIs and TCAs in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999;21:296-308.
Anderson I. Meta-analytical studies on new antidepressants. Br Med Bull 2001;57:161-178.
Thase ME, Entsuah R, Ahmed S. et al. Meta-Analysis of randomized controlled trials comparing venlafaxine and SSRIs: The evidence revisited. Prestented at the APA, Atlanta 2005.
Hansen RA, Gartlehner G, Lohr KN et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005; 143:415-426.
Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther. 1998 May-Jun;20(3):517-26.
Rudolph RL, Fabre LF, Feighner JP et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998 Mar;59(3):116-22.
Guelfi JD, White C, Hackett D et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry. 1995 Oct;56(10):450-8.
Montgomery SA, Entsuah R, Hackett D et al. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry. 2004 Mar;65(3):328-36.
Entsuah R. Venlafaxine vs. SSRIs: Comparison of somatic symptom reduction. New York, USA Congress of the American Psychiatric Association (APA) 2004.
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001 Dec;25(6):871-80.
Pitsikas N. Duloxetine Eli Lilly & Co. Curr Opin Investig Drugs. 2000 Sep;1(1):116-21.
Turcotte JE, Debonnel G, de Montigny C et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001 May;24(5):511-21.
Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000 Feb;40(2):161-7.
Skinner MH, Skerjanec A, Seger M, Hewitt R. The effect of food and bedtime administration an duloxetine pharmacokinetics. Clin Pharmacol Ther. 2000; 67:129.
Kirwin JL, Goren JL. Duloxetine. An antidepressant that inhibits both norepinephrine and serotonin uptake. Formulary 2003;38:29-37.
Nemeroff CB, Schatzberg AF, Goldstein DJ et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002 Autumn;36(4):106-32.
Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry. 2003 Oct;64(10):1237-44.
Thase ME, Joliat MJ, Detke, MJ. Remission in placebo-controlled trials of duloxetine with an SSRI comparator [abstract]. Biol Psychiatry 2004;55:37S.
Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002 Apr;63(4):308-15.
Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002 Nov-Dec;36(6):383-90.
Brannan SK, Mallinckrodt CH, Brown EB et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res. 2005 Jan;39(1):43-53.
Mallinckrodt CH, Goldstein DJ, Detke MJ et al. Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression. Prim Care Companion J Clin Psychiatry. 2003 Feb;5(1):19-28.
Raskin J, Pritchett YL, Chappell AS et al. Duloxetine in the treatment of diabetic peripheral neuropathic pain - results from three clinical trials. Poster, APA, Atlanta, GA, 2005.
Arnold LM, Crofford LJ, Wohlreich M et al. (2004) A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without depressive disorder. Duloxetine Fibromyalgia Trial Group. Arth Rheum 2004;50:2974-84.
Preti A. Tomoxetine (Eli Lilly & Co). Curr Opin Investig Drugs. 2002 Feb;3(2):272-7.
Banaschewski T, Roessner V, Dittmann RW et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I102-16.
Wong EH, Sonders MS, Amara SG et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry. 2000 May 1;47(9):818-29.
Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27.
Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol. 1997 Apr;7 Suppl 1:S23-35.
Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol. 1997;11(4 Suppl):S9-15.
Hajos M, Fleishaker JC, Filipiak-Reisner JK et al. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev. 2004 Spring;10(1):23-44.
Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol. 2000 Feb;20(1):28-34.
Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol. 1997;11(4 Suppl):S9-15.
Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol. 1997 Apr;7 Suppl 1:S37-47.
Montgomery SA. Chairman's overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry. 1998;59 Suppl 14:26-9.
Massana J, Möller HJ, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol. 1999 Mar;14(2):73-80.
Andreoli V, Caillard V, Deo RS et al. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol. 2002 Aug;22(4):393-9.
Eker SS, Akkaya C, Akgöz S et al. Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder. Turk Psikiyatri Derg. 2005 Fall;16(3):153-63.
Katona C, Bercoff E, Chiu E et al. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J Affect Disord. 1999 Oct;55(2-3):203-13.
Rampello L, Chiechio S, Nicoletti G et al. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berl). 2004 Apr;173(1-2):73-8.
Rampello L, Alvano A, Chiechio S et al. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study. Arch Gerontol Geriatr. 2005 May-Jun;40(3):275-85.
Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry. 1999 Jun;60(6):400-6.
Kasper S, el Giamal N, Hilger E. Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82.
Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992 Feb;149(2):195-8.
Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991 Jul;148(7):910-6.
Bauer M, Whybrow PC, Angst J et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002 Jan;3(1):5-43.
Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry. 1985 Jun;46(6):206-9.
Schmauss M, Kapfhammer HP, Meyr P, Hoff P. Combined MAO-inhibitor and tri- (tetra) cyclic antidepressant treatment in therapy resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(4):523-32.
Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study. J Affect Disord. 2005 Dec;89(1-3):183-8.
Adli M, Baethge C, Heinz A et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):387-400.
Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002 Nov;159(11):1869-75.
Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003 Feb;64(2):208-14.
Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999 Mar;20(3):226-47.
Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 Sep;306(3):954-64.
Tuma J, Strubbe JH, Mocaër E, Koolhaas JM. S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delays of circadian rhythms of the rat. Chronobiol Int. 2001 Sep;18(5):781-99.
Tenn CC, Niles LP. The antidopaminergic action of S-20098 is mediated by benzodiazepine/GABA(A) receptors in the striatum. Brain Res. 1997 May 9;756(1-2):293-6.
Bogaards JJ, Hissink EM, Briggs M et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur J Pharm Sci. 2000 Dec;12(2):117-24.
Le Quellec A, Dupin S, Tufenkji AE et al. Microdialysis: an alternative for in vitro and in vivo protein binding studies. Pharm Res. 1994 Jun;11(6):835-8.
Lôo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002 Sep;17(5):239-47.
Olie JP, Emsley R. Confirmed clinical efficacy of agomelatine (25-50 mg) in major depression: two randomized, double-blind, placebo-controlled studies. Eur Neuropsychopharmacol 2005;15:S416.
Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006 Feb;16(2):93-100.
Loo H, Dalery J, Macher JP, Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders. Encephale. 2002 Jul-Aug;28(4):356-62.
den Boer JA, Bosker FJ, Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol. 2006 Feb;21 Suppl 1:S21-4.
Montgomery SA, Kennedy SH, Burrows GD et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004 Sep;19(5):271-80.
Van Reeth O, Olivares E, Zhang Y et al. Chronobiotic effects of gepirone, a potential antidepressant with 5HT1A receptor partial agonist properties. Behav Pharmacol. 1999 Mar;10(2):119-30.
Silva RC, Brandao ML. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis. Pharmacol Biochem Behav 2000;65:209-216.
Feiger AD. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull. 1996;32(4):659-65.
Wilcox CS, Ferguson JM, Dale JL, Heiser JF. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull. 1996;32(3):335-42.
Feiger AD, Heiser JF, Shrivastava RK et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry. 2003 Mar;64(3):243-9.
Kramer MS, Cutler N, Feighner J et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998 Sep 11;281(5383):1640-5.
Stout SC, Owens MJ, Nemeroff CB. Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol. 2001;41:877-906.
Kramer MS, Winokur A, Kelsey J et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004 Feb;29(2):385-92.
Zobel AW, Nickel T, Künzel HE et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res. 2000 May-Jun;34(3):171-81.
Murphy BE. Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Mol Biol. 1991 Aug;39(2):239-44.
Wolkowitz OM, Reus VI, Manfredi F et al. Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry. 1993 May;150(5):810-2.
Anand A, Malison R, McDougle CJ, Price LH. Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report. Biol Psychiatry. 1995 Mar 1;37(5):338-40.
Ghadirian AM, Engelsmann F, Dhar V et al. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry. 1995 Mar 15;37(6):369-75.
Thakore JH, Dinan TG. Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry. 1995 Mar 15;37(6):364-8.
Sovner R, Fogelman S. Ketoconazole therapy for atypical depression. J Clin Psychiatry. 1996 May;57(5):227-8.
Wolkowitz OM, Reus VI, Chan T et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry. 1999 Apr 15;45(8):1070-4.
Malison RT, Anand A, Pelton GH et al. Limited efficacy of ketoconazole in treatment-refractory major depression. J Clin Psychopharmacol. 1999 Oct;19(5):466-70.
Murphy BE, Dhar V, Ghadirian AM et al. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol. 1991 Apr;11(2):121-6.
Raven PW, O'Dwyer AM, Taylor NF, Checkley SA. The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles. Psychoneuroendocrinology. 1996 Apr;21(3):277-86.
O'Dwyer AM, Lightman SL, Marks MN, Checkley SA. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord. 1995 Feb 21;33(2):123-8.
Jahn H, Schick M, Kiefer F et al. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004 Dec;61(12):1235-44.
Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 1999 Sep;22(9):410-6.
Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3-hydroxy-5[]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res 1991;561:157-161.
Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav. 2000 Sep;67(1):137-43.
Rupprecht R. The neuropsychopharmacological potential of neuroactive steroids. J Psychiatr Res. 1997 May-Jun;31(3):297-314.
Wolkowitz OM, Reus VI, Keebler A et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999 Apr;156(4):646-9.
Wolkowitz OM, Reus VI, Roberts E et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry. 1997 Feb 1;41(3):311-8.
Heuser I, Deuschle M, Luppa P et al. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab. 1998 Sep;83(9):3130-3.
Murphy BE, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci. 1993 Nov;18(5):209-13.
Belanoff JK, Rothschild AJ, Cassidy F et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002 Sep 1;52(5):386-92.
Belanoff JK, Flores BH, Kalezhan M et al. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001 Oct;21(5):516-21.
Deltito J, Beyer D. The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression. J Affect Disord. 1998 Dec;51(3):345-51.
Shelton RC, Keller MB, Gelenberg A et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001 Apr 18;285(15):1978-86.
Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry. 2001 May;34(3):96-103.
Kasper S. Hypericum perforatum--a review of clinical studies. Pharmacopsychiatry. 2001 Jul;34 Suppl 1:S51-5.
Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002 Aug;159(8):1361-6.
Uebelhack R, Gruenwald J, Graubaum HJ, Busch R. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther. 2004 Jul-Aug;21(4):265-75.
Wong AH, Smith M, Boon HS. Herbal remedies in psychiatric practice. Arch Gen Psychiatry 1998;55:1033-1044.
Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther. 2002 Jan-Feb;19(1):43-52.
Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000 Mar;15(2):61-8.
Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ. 2005 Mar 5;330(7490):503.
Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther. 2000 Apr;22(4):411-9.
Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 2005;38:78-86.
Volz HP, Laux P. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. Compr Psychiatry. 2000 Mar-Apr;41(2 Suppl 1):133-7.
Fava M, Alpert J, Nierenberg AA et al. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct;25(5):441-7.
Bjerkenstedt L, Edman GV, Alken RG, Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci. 2005 Feb;255(1):40-7.
Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ. 1999 Dec 11;319(7224):1534-8.
Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ. 2000 Sep 2;321(7260):536-9.
Kim HL, Streltzer J, Goebert D. St. John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis. 1999 Sep;187(9):532-8.
Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed outpatients. A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology (Berlin) 2002;164:301-308.
Trautmann-Sponsel RD, Dienel A. Safety of Hypericum extract in mildly to moderately depressed outpatients: a review based on data from three randomized, placebo-controlled trials. J Affect Disord. 2004 Oct 15;82(2):303-7.
Czekalla J, Gastpar M, Hübner WD, Jäger D. The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry. 1997 Sep;30 Suppl 2:86-8.
Kasper S, Schulz V. High dose St. John's wort extract as a phytogenic antidepressant. Wien Med Wochenschr 1999;149:191-196.
Madabushi R, Frank B, Drewelow B et al. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol. 2006 Mar;62(3):225-33.
Johne A, Brockmöller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther. 1999 Oct;66(4):338-45.
